153 completed, 21 unknown, 17 terminated, 6 recruiting. 57 Phase 4, 37 Phase 3, 35 Phase 1, 32 Not applicable, 26 Phase 2.
Follow this drug Literature Review of Paroxetine trials Research Report on Paroxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia Paroxetine Hydrochloride, Ascorbic acid (Vitamin C) - Preeclampsia, Endothelial Function | Early Phase 1 | Recruiting | Anna Stanhewicz, PhD | 40 | 2026-08-30 | 2026-07-29 |
| A Phase I Study of NS-079 in Healthy Participants Placebo, NS-079 tablet, Paroxetine - Healthy Adult Participants | Phase 1 | Recruiting | NeuShen Therapeutics | 78 | 2026-07-30 | 2026-09-15 |
| Deprescription of Antidepressants in Primary Care (DAPriCare) Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) - Deprescription, Antidepressants | Early Phase 1 | Not yet recruiting | University of Huelva | 325 | 2026-06-01 | 2026-05-04 |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors BNT326, Pumitamig, Itraconazole - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 1438 | 2025-08-12 | 2026-10-09 |
| Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy Paroxetine 20 Mg Oral Tablet - Premature Ejaculation | Not applicable | Not yet recruiting | South Valley University | 60 | 2025-07-01 | 2025-07-09 |
| Management of Acute Tinnitus With Migraine Medications Nortriptyline, Topiramate, Paroxetine - Tinnitus | Phase 4 | Active not recruiting | University of California, Irvine | 100 | 2025-06-01 | 2025-10-10 |
| Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study) Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine) - Cardiovascular Diseases (CVD), Depression Anxiety Disorder | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 106 | 2025-04-22 | 2025-06-17 |
| Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause Paroxetine, Placebo - Menopause Syndrome, Menopause Surgical | Phase 2 | Completed | Universidad Nacional Autonoma de Honduras | 90 | 2025-01-30 | 2025-09-17 |
| Neurobiological and Genomic Predictors of Relapse in Depression Antidepressant Medications - Healthy, Major Depressive Disorder (MDD) | Recruiting | Mehmet Kemal Arikan | 204 | 2025-01-01 | 2026-01-09 | |
| Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants SSRI - Depression, Inflammation | Completed | Germans Trias i Pujol Hospital | 50 | 2024-04-01 | 2026-09-14 | |
| Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction | Phase 1 | Completed | Asceneuron S.A. | 50 | 2024-02-22 | 2024-12-18 |
| Paroxetine Safety and Efficacy in Rheumatoid Arthritis Methotrexate, Paroxetine - Rheumatoid Arthritis | Phase 3 | Completed | Mostafa Bahaa | 100 | 2024-01-31 | 2026-05-04 |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Paroxetine, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Unknown | aya ramadan ashmawy sarhan | 44 | 2024-01-01 | 2024-01-12 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats Fezolinetant, Paroxetine, Citalopram - Hot Flashes | Completed | Astellas Pharma Global Development, Inc. | 999 | 2023-11-15 | 2026-06-05 | |
| Concentration-QT Study of Paroxetine in Healthy Adults Paroxetine - Anxiety Disorders | Phase 1 | Completed | GlaxoSmithKline | 38 | 2023-10-02 | 2026-08-19 |
| Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 37 | 2023-08-22 | 2024-01-25 |
| Effects of Paroxetine on Cardiovascular Function in Septic Patients Paroxetine - Septic Shock, Sepsis | Phase 2 | Completed | Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | 130 | 2023-06-10 | 2026-08-24 |
| Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome Vortioxetine 20Mg Tab, Paroxetine 20 Mg Oral Tablet, Sertraline 50 MG - Burning Mouth Syndrome | Phase 3 | Unknown | Federico II University | 203 | 2023-01-01 | 2023-09-06 |
| Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects Paroxetine, Lysergic Acid Diethylamide, Placebo - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 24 | 2022-10-24 | 2024-03-13 |
Showing 20 of 205. Sign in to see all of them.
Depression (51) · Depressive Disorder, Major (41) · Anxiety Disorders (18) · Stress Disorders, Post-Traumatic (18) · Panic Disorder (15) · Depressive Disorder (13) · Phobia, Social (10) · Generalized Anxiety Disorder (9) · Obsessive-Compulsive Disorder (8) · Bipolar Disorder (7) · Hot Flashes (7) · Mental Disorders (7) · Mood Disorders (4) · Premature Ejaculation (4) · Dementia (3)
GlaxoSmithKline (23) · Samsung Medical Center (7) · US Department of Veterans Affairs (6) · Pfizer (5) · Duke University (4) · Emory University (4) · Mylan Pharmaceuticals Inc (4) · New York State Psychiatric Institute (4) · Noven Therapeutics (4) · Sanofi (4) · University of Pittsburgh (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · AstraZeneca (3) · Capital Medical University (3) · Eli Lilly and Company (3)
United States (89) · Canada (17) · South Korea (15) · China (14) · Germany (14) · France (8) · Brazil (7) · Australia (6) · Mexico (6) · Norway (6) · South Africa (6) · Finland (5) · Italy (5) · Spain (5) · Sweden (5)
Doh Kwan Kim, M.D., Ph.D. (4) · Robin Kroll, MD (3) · Arthur Waldbaum, MD (2) · Ashley Tunkle, MD (2) · Ashwin A Patkar, M.D. (2) · Benoit Girard, MD (2) · Bruce T Czarnik, M.D. (2) · Cynthia Strout, MD (2) · D. S. Harnsberger, MD (2) · David J Portman, MD (2)
PMID 24045678, PMID 24552977, PMID 25080392, PMID 25137243, PMID 11765093, PMID 15005752, PMID 15110730, PMID 15330403, PMID 15349007, PMID 15465989, PMID 15541061, PMID 15569893, PMID 15677618, PMID 15723025, PMID 15898966, PMID 15950022, PMID 15960566, PMID 16023735, PMID 16168792, PMID 16176440, PMID 16197928, PMID 16338761, PMID 16339615, PMID 16339616, PMID 16426088, PMID 16448626, PMID 16449473, PMID 16449474, PMID 16540613, PMID 16552982, PMID 16566627, PMID 16595351, PMID 16635643, PMID 16675760, PMID 16677228, PMID 16816280, PMID 16816301, PMID 16928441, PMID 17007487, PMID 17042830, PMID 17069768, PMID 17392295, PMID 17404119, PMID 17451562, PMID 17728418, PMID 17868655, PMID 18227782, PMID 18399724, PMID 18457338, PMID 18517289
2016 (3), 2018 (2), K23MH076049 (2), 2004 (1), 2005 (1), 2009 (1), 2014 (1), K23DA017307 (1), P30MH075673 (1), R01AA013379 (1), R01MH045963 (1), R01MH045964 (1), R01MH045965 (1), R01MH045966 (1), R01MH055121 (1)